With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.
An article from
China competition
With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.
Published Sept. 3, 2026
A GSK logo is seen on the side of an office building in Poznan, Poland.
GSK to spend $110M upfront licensing Hutchmed's KRAS-EGFR cancer drug HMPL-A830, up to $1.295B total, pending antitrust clearance.
The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker…
GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer…
The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access…
Antibody-drug conjugates from Kelun-Biotech and Hansoh Pharma, respectively partnered with Merck & Co. and GSK, delivered…
In a landmark moment for its oncology ambitions, GSK has
